Great Point Partners LLC Invests $15.77 Million in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Great Point Partners LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,338,568 shares of the specialty pharmaceutical company’s stock, valued at approximately $15,768,000. KalVista Pharmaceuticals accounts for 3.0% of Great Point Partners LLC’s holdings, making the stock its 13th biggest holding. Great Point Partners LLC owned approximately 3.17% of KalVista Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC purchased a new stake in KalVista Pharmaceuticals during the fourth quarter worth about $507,000. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 11.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after buying an additional 383,435 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 101.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock worth $95,000 after buying an additional 4,043 shares in the last quarter. BNP Paribas Financial Markets boosted its position in KalVista Pharmaceuticals by 94.5% in the 1st quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock valued at $214,000 after buying an additional 8,750 shares during the period. Finally, ClariVest Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the first quarter worth $659,000.

KalVista Pharmaceuticals Trading Down 6.8 %

Shares of KALV opened at $9.78 on Tuesday. The firm has a market capitalization of $412.60 million, a price-to-earnings ratio of -2.88 and a beta of 0.89. The firm’s fifty day simple moving average is $12.82 and its 200-day simple moving average is $12.17. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.21 and a twelve month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. On average, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,352 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the transaction, the chief executive officer now directly owns 250,800 shares in the company, valued at $3,057,252. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the sale, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the transaction, the chief executive officer now owns 250,800 shares in the company, valued at approximately $3,057,252. The disclosure for this sale can be found here. Insiders sold a total of 30,804 shares of company stock worth $372,112 over the last 90 days. 12.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KALV. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.